Literature DB >> 12928785

Transducing proteins to manipulate intracellular targets.

Friedrich C Luft1.   

Abstract

Mesh：

Substances：

Year:  2003        PMID： 12928785     DOI： 10.1007/s00109-003-0473-4

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN： 0946-2716            Impact factor:   4.599


× No keyword cloud information.
  14 in total

1.  Can VP22 resurrect gene therapy?

Authors:  F C Luft
Journal:  J Mol Med (Berl)       Date:  1999-08       Impact factor: 4.599

2.  A novel approach to induce cell cycle reentry in terminally differentiated muscle cells.

Authors:  Wolfgana Derer; Hariharan P Easwaran; Heinrich Leonhardt; M Cristina Cardoso
Journal:  FASEB J       Date:  2001-11-29       Impact factor: 5.191

3.  Intercellular delivery of thymidine kinase prodrug activating enzyme by the herpes simplex virus protein, VP22.

Authors:  M S Dilber; A Phelan; A Aints; A J Mohamed; G Elliott; C I Smith; P O'Hare
Journal:  Gene Ther       Date:  1999-01       Impact factor: 5.250

Review 4.  Protein transduction: a novel tool for tissue regeneration.

Authors:  M Cristina Cardoso; Heinrich Leonhardt
Journal:  Biol Chem       Date:  2002-10       Impact factor: 3.915

5.  Intercellular delivery of functional p53 by the herpesvirus protein VP22.

Authors:  A Phelan; G Elliott; P O'Hare
Journal:  Nat Biotechnol       Date:  1998-05       Impact factor: 54.908

6.  Intercellular trafficking and protein delivery by a herpesvirus structural protein.

Authors:  G Elliott; P O'Hare
Journal:  Cell       Date:  1997-01-24       Impact factor: 41.582

7.  VP22 enhanced intercellular trafficking of HSV thymidine kinase reduced the level of ganciclovir needed to cause suicide cell death.

Authors:  C S Liu; B Kong; H H Xia; K A Ellem; M Q Wei
Journal:  J Gene Med       Date:  2001 Mar-Apr       Impact factor: 4.565

8.  VP22-mediated intercellular transport of p53 in hepatoma cells in vitro and in vivo.

Authors:  Lars Zender; Florian Kühnel; Reiner Köck; Michael Manns; Stefan Kubicka
Journal:  Cancer Gene Ther       Date:  2002-06       Impact factor: 5.987

9.  Enhanced suicide gene effect by adenoviral transduction of a VP22-cytosine deaminase (CD) fusion gene.

Authors:  W A Wybranietz; C D Gross; A Phelan; P O'Hare; M Spiegel; F Graepler; M Bitzer; P Stähler; M Gregor; U M Lauer
Journal:  Gene Ther       Date:  2001-11       Impact factor: 5.250

10.  Inhibition of NF-kappaB by a TAT-NEMO-binding domain peptide accelerates constitutive apoptosis and abrogates LPS-delayed neutrophil apoptosis.

Authors:  Mira Choi; Susanne Rolle; Maren Wellner; M Cristina Cardoso; Claus Scheidereit; Friedrich C Luft; Ralph Kettritz
Journal:  Blood       Date:  2003-05-22       Impact factor: 22.113
View more
  4 in total

1.  Successful TAT-mediated enzyme replacement therapy in a mouse model of mitochondrial E3 deficiency.

Authors:  Matan Rapoport; Lina Salman; Ofra Sabag; Mulchand S Patel; Haya Lorberboum-Galski
Journal:  J Mol Med (Berl)       Date:  2010-11-16       Impact factor: 4.599

2.  Tat-Mediated Peptide Intervention in Analgesia and Anesthesia.

Authors:  Feng Tao; Roger A Johns
Journal:  Drug Dev Res       Date:  2010-04-01       Impact factor: 4.360

3.  Replacement of the C6ORF66 assembly factor (NDUFAF4) restores complex I activity in patient cells.

Authors:  Dana Marcus; Michal Lichtenstein; Ann Saada; Haya Lorberboum-Galski
Journal:  Mol Med       Date:  2013-07-24       Impact factor: 6.354

4.  TAT-MTS-MCM fusion proteins reduce MMA levels and improve mitochondrial activity and liver function in MCM-deficient cells.

Authors:  Tal Erlich-Hadad; Rita Hadad; Anat Feldman; Hagar Greif; Michal Lictenstein; Haya Lorberboum-Galski
Journal:  J Cell Mol Med       Date:  2017-12-19       Impact factor: 5.310
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.